Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | UNG | P13051 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20068150 | 0.91 | TP53 (0.62) | POLBHPGDTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL3126652 | 0.88 | MAPT (0.54) | POLBHPGDTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL9097849 | 0.87 | LMNA (0.60) | POLBHPGDTP53UNGSMN1; SMN2 | |
| SCHEMBL16618744 | 0.87 | CYP4F2 (0.54) | POLBHPGDTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL128386 | 0.87 | CYP4F2 (0.54) | POLBHPGDTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL20613727 | 0.86 | SMN1; SMN2 (0.59) | POLBHPGDTP53UNGSMN1; SMN2 | |
| SCHEMBL13521535 | 0.86 | UNG (0.59) | POLBHPGDTP53UNGSMN1; SMN2 | |
| SCHEMBL16618788 | 0.85 | CYP4F2 (0.52) | POLBHPGDTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL1506219 | 0.85 | CYP4F2 (0.52) | POLBHPGDTP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL9099896 | 0.84 | L3MBTL1 (0.54) | HPGDTP53UNGSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3951993-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | claimed |
| CN-119390668-A | Compound with ketoxime ether structure and application thereof | 复旦大学 | 2025-02-07 | — | — | CN | disclosed |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| EP-4308554-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | The Board of Trustees of the University of Illinois (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197658-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-09-22 | — | — | WO | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| US-9789118-B2 | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-10-17 | — | — | US | disclosed |
| EP-2598486-B1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-28 | — | — | EP | disclosed |
| CN-103339111-B | Bicyclic acetyl-CoA carboxylase inhibitors | NOVARTIS AG (CH) | 2015-12-16 | — | — | CN | disclosed |
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-3971790-A | VASODILATION, HYPOTENSIVE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
| US-3971791-A | VASODILATION, HYPOTENSIVE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
| US-3971796-A | 1,4-Dihydropyridine esters | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-27 | — | — | US | disclosed |
| US-3959474-A | 2,6-Diamino-1,4-dihydropyridine-3,5-dicarboxylic acid esters used as coronary vessel dilators and anti-hypertensive agents | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-25 | — | — | US | disclosed |
| US-3957998-A | ADMINISTERING | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-18 | — | — | US | disclosed |
| US-3951993-A | HYPOTENSIVE, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3950336-A | HYPOTENSIVE AGENTS, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-04-13 | — | — | US | disclosed |
| US-3946026-A | HYPOTENSIVE AGENTS, CORONARY VESSEL DILATORS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-03-23 | — | — | US | disclosed |
| US-3939171-A | HYPOTENSIVE, VASODILATION | BAYER AKTIENGESELLSCHAFT (DT) | 1976-02-17 | — | — | US | disclosed |
| US-3935223-A | 2-Amino-1,4-dihydropyridine derivatives | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171363-A1 | BICYCLIC ACETYL-COA CARBOXYLASE INHIBITORS AND USES THEREOF | ACACA, ACACB, COASY | POLB 1792/4885HPGD 526/4885TP53 3890/4885 |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | SREBF2, SREBF1, SLC2A2 | POLB 3056/4885HPGD 1403/4885TP53 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.